		Main Operating Appropriations Bill H.B. 33
As Passed By House	As Passed By Senate	As Reported By Conference Committee
R.C. 3796.32		R.C. 3796.32
Same as the Executive.	No provision; see COMCD18.	Same as the Senate.
Fiscal effect: Same as the Executive.		
pharmacists, pharmacy interns, and pharmacy technicia	ns	
	R.C. 4729.41	
No provision.	Authorizes certified pharmacy technicians and registered pharmacy technicians to administer immunizations in the same manner as pharmacy interns under current law.	No provision.
No provision.	Authorizes pharmacists, interns, and technicians to administer immunizations beginning when a child is age 5, as opposed to the current law age limit of 7.	No provision.
No provision.	Eliminates, for children under age 13, a requirement that their immunizations be prescribed (immunizations for COVID-19 and the flu do not require a prescription under current law or the amendment).	No provision.
	R.C. 3796.32 Same as the Executive. Fiscal effect: Same as the Executive. pharmacists, pharmacy interns, and pharmacy technicia No provision. No provision.	R.C. 3796.32 Same as the Executive. No provision; see COMCD18. Fiscal effect: Same as the Executive. Pharmacists, pharmacy interns, and pharmacy technicians R.C. 4729.41 No provision. Authorizes certified pharmacy technicians to administer immunizations in the same manner as pharmacy interns under current law. No provision. Authorizes pharmacists, interns, and technicians to administer immunizations beginning when a child is age 5, as opposed to the current law age limit of 7. No provision. Eliminates, for children under age 13, a requirement that their immunizations be prescribed (immunizations for COVID-19 and the flu do not require a prescription under

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Reported By Conference Committee
No provision.	No provision.	Requires, for each immunization administered to a child under age 18, that the pharmacist, intern, or technician inform the child's parent or legal guardian of the importance of well child visits with a pediatrician or other primary care provider, and refer patients when appropriate.	No provision.
		Fiscal effect: Potential minimal annual increase in PRX compliance inspection and enforcement costs.	

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Reported By Conference Committee
PRXCD4 Terminal distributor li	cense exemptions		
		R.C. 4729.541, conforming changes in R.C. 4729.51, 4729.55	R.C. 4729.541, conforming changes in R.C. 4729.51, 4729.55
No provision.	No provision.	Adds the following exemptions from licensure as a terminal distributor of dangerous drugs: (1) a person who possesses nitrous oxide for use as a direct ingredient in food under federal regulations or for testing or maintaining a plumbing or HVAC system; (2) a person who possesses medical oxygen, sterile water, or sterile saline for direct patient administration or for installing or maintaining home medical equipment; and (3) a person who possesses controlled substances and other dangerous drugs for dog training in conjunction with a law enforcement agency.	Same as the Senate.
		Fiscal effect: Loss of 221 licenses and approximately \$82,720 in fee revenue collected biennially and credited to the Occupational Licensing and Regulatory Fund (Fund 4K90). Reduction in workload for PRX licensing and inspection staff.	Fiscal effect: Same as the Senate.

State Board of Pharmacy				Main (Operating Appropriations B H.B.
Executive	As Passed By House	As Passo	ed By Senate	As Repo	rted By Conference Committee
PRXCD5 Repeal of office-based opioid treatr	ment (OBOT) licensure				
		R.C.	4729.553, (Repealed), conforming changes in numerous other R.C. sections and Section 747.30	R.C.	4729.553, (Repealed), conforming changes in numerous other R.C. sections and Section 747.30
No provision.	No provision.	distribut office-bac classifica clinics, a	es PRX's licensure of terminal tors of dangerous drugs with an ased opioid treatment (OBOT) ation, which is required for facilities, and other locations providing OBOT than 30 patients.	Same as	the Senate.
		approxi collecte Occupa (Fund 4	fect: Loss of 146 licenses and mately \$64,240 in fee revenue d biennially and credited to the cional Licensing and Regulatory Fund K90). Reduction in workload for PRX g and inspection staff.	Fiscal eff	fect: Same as the Senate.
PRXCD1 Cash transfer from the Medical Mai	rijuana Control Program Fund to the Drug Database Fund				
Section: 367.10	Section: 367.10	Section:	367.10	Section:	367.10
Permits the COM Director, upon request of the PRX Director, to certify an amount needed for the operation of PRX's drug database in each fiscal year. Permits the transfer of that amount from the Medical Marijuana Control Program Fund (Fund 5YSO), used by COM, to the Drug Database Fund (Fund 5SGO), used by PRX.	Same as the Executive.	provisio each fise Director from Fu Controll transfer	s the Executive provision with a n that permits the PRX Director, in cal year, to certify to the OBM an amount in cash to be transferred and 5SYO to Fund 5SGO, and upon ing Board approval, appropriates any red amounts. Makes technical on to reference "Fund 5SYO" instead if 5YSO".	Same as	the Senate.

State 1	State Board of Pharmacy					Main Operating Appropriations Bill H.B. 33	
Executiv	ve	As Pass	ed By House	As Pass	ed By Senate	As Rep	orted By Conference Committee
COMCD1	18 Division of Marijuana Control and trans	sfer of Med	ical Marijuana Control Program				
R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06	R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06	R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4729.80, 4729.86, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06	R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4729.80, 4729.86, 4776.01; Section 525.20, 737.50; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06
(DMC) w COM to Control	the Division of Marijuana Control vithin COM and requires PRX and transfer the Medical Marijuana Program (MMCP) to DMC no later cember 31, 2023.	Same a	s the Executive.	Same a	s the Executive.	Same a	s the Executive.
	hes a Superintendent of Marijuana to oversee DMC.	Same a	s the Executive.	Same a	s the Executive.	Same a	s the Executive.
issued b the rem of medic remain a	s that licenses and registrations by COM and PRX remain in effect for ainder of their term and that forms cal marijuana approved by PRX approved unless that approval is later by DMC.	Same a	s the Executive.	Same a	s the Executive.	Same a	s the Executive.
MMCP r amende review a	s that COM and PRX rules related to remain in effect until repealed or ed by DMC, but requires DMC to and propose revisions to existing rules I dispensaries no later than March 1,	Same a	s the Executive.	Same a	s the Executive.	Same a	s the Executive.

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Reported By Conference Committee
Allows DMC to investigate alleged violations of the Medical Marijuana Law, including by subpoenaing documents and witnesses.	Same as the Executive.	Same as the Executive.	Same as the Executive.
Requires PRX to grant DMC access to the Ohio Automated Rx Reporting System (OARRS) as needed to ensure compliance with the Medical Marijuana Law.	Same as the Executive.	Replaces the Executive provision with one that requires PRX, on receipt of a request from a designated representative of DMC, to provide to the representative information from OARRS relating to an individual who, or entity that, is the subject of an active investigation being conducted by DMC.	Same as the Senate.
Makes conforming changes throughout the Revised Code.	Same as the Executive.	Same as the Executive.	Same as the Executive.
No provision.	No provision.	No provision.	Allows holders of a provisional medical marijuana dispensary license who missed their initial operation deadline until December 31, 2023, to demonstrate compliance with dispensary operational requirements and begin operations and specifies disciplinary actions against holders if certain deadlines are not met.
No provision.	No provision.	No provision.	Does all of the following in relation to the MMCP transfer: (1) provides for the transfer of PRX employees to COM, (2) authorizes OBM to make budget and accounting changes necessary to facilitate the transfer, (3) specifies that no action or proceeding on the effective date of the MMCP transfer is affected by the transfer, and (4) requires LSC to renumber rules of PRX regulating MMCP to reflect the transfer to COM.

State Board of Pharmacy	Main Operating Appropriations Bill H.B. 33		
Executive	As Passed By House	As Passed By Senate	As Reported By Conference Committee
Fiscal effect: Increases costs for COM for overseeing PRX's portion of MMCP, and simultaneously reduces costs for PRX. The executive provides funding for these purpose under Fund 5SYO ALI 800650, Medical Marijuana Control Program.	Fiscal effect: Same as the Executive.	Fiscal effect: Same as the Executive.	Fiscal effect: Same as the Executive.

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Reported By Conference Committee
MEDCD2 Legacy pain manageme	ent study committee		
	Section: 335.20	Section: 335.20	Section: 335.20
No provision.	Establishes the Legacy Pain Management Study Committee to study and evaluate the care and treatment of patients suffering from chronic or debilitating pain, in particular those who have been prescribed opioids for lengthy periods of time, often referred to as legacy patients.	Same as the House.	Same as the House.
No provision.	Includes the following as members of the committee: four members of the General Assembly, one representative of OhioMHAS, one representative of SMBO, one representative of PRX, one member representing patients, and one member representing prescribers.	Same as the House.	Same as the House.
No provision.	Requires the committee to consider several topics relating to legacy patients, including the availability of and access to pain management specialists in Ohio and the challenges associated with tapering opioid doses.	Same as the House.	Same as the House.
No provision.	Requires the committee, by December 1, 2024, to prepare and submit to the General Assembly a report of its recommendations for legislation to address the care and treatment of legacy patients.	Same as the House.	Same as the House.
	Fiscal effect: Minimal.	Fiscal effect: Same as the House.	Fiscal effect: Same as the House.

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Reported By Conference Committee
MHACD21 Mobile-based opioid use disorder treat	ment		
Section: 337.95	Section: 337.95		
Requires OhioMHAS to operate a pilot program during FY 2024 and FY 2025 to provide opioid use disorder treatment to individuals in underserved regions selected by OhioMHAS, using medication units that are mobile.	Same as the Executive.	No provision.	No provision.
Specifies that the purpose of the program is to extend access to medication-assisted treatment to areas of the state lacking licensed opioid treatment programs and qualifying practitioners.	Same as the Executive.	No provision.	No provision.
Requires OhioMHAS to ensure that the services provided in mobile medication units used in the pilot program are those specified in relevant guidance issued by the U.S. Substance Abuse and Mental Health Services Administration.	Same as the Executive.	No provision.	No provision.
Requires PRX, SMBO, and NUR and any other state agency that OhioMHAS determines may be of assistance in accomplishing the pilot program's purpose to provide assistance upon request from OhioMHAS.	Same as the Executive.	No provision.	No provision.
Requires OhioMHAS to develop a plan for implementing and evaluating the pilot program within 60 days of the section's effective date.	Same as the Executive.	No provision.	No provision.

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Reported By Conference Committee
Requires OhioMHAS to complete a report of the findings obtained from the program within six months after the conclusion of the pilot program.	Same as the Executive.	No provision.	No provision.
Earmarks \$750,000 in each fiscal year in GRF ALI 336504, Community Innovations, to operate the pilot program.	Same as the Executive.	No provision.	No provision.